GemVax&KAEL Co.,Ltd. Stock

Equities

A082270

KR7082270000

Semiconductors

End-of-day quote Korea S.E. 06:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
11,060 KRW -0.18% Intraday chart for GemVax&KAEL Co.,Ltd. +0.18% -16.72%
Sales 2022 75.8B 55.19M Sales 2023 72.21B 52.57M Capitalization 523B 381M
Net income 2022 -19.6B -14.27M Net income 2023 -27.18B -19.78M EV / Sales 2022 5.67 x
Net cash position 2022 35.37B 25.75M Net cash position 2023 6.16B 4.48M EV / Sales 2023 7.16 x
P/E ratio 2022
-23.1 x
P/E ratio 2023
-19.2 x
Employees 181
Yield 2022 *
-
Yield 2023
-
Free-Float 72.3%
More Fundamentals * Assessed data
Dynamic Chart
GemVax&KAEL Co.,Ltd. announced that it has received KRW 17.6 billion in funding from Kiwoom Asset Management Co., Ltd., J&J Assets Management Ltd., Youngjin Industry Co., Ltd. and other investors CI
GemVax&KAEL Co.,Ltd. announced that it expects to receive KRW 17.6 billion in funding from Kiwoom Asset Management Co., Ltd., J&J Assets Management Ltd., Youngjin Industry Co., Ltd. and other investors CI
Gemvaxlink Co., Ltd. announced that it has received KRW 29.099978456 billion in funding from GemVax&KAEL Co.,Ltd., Keonyang Co., Ltd., Wingbridge I&D Co., Ltd., Kaffaint Co. Ltd and other investors CI
Tranche Update on GemVax&KAEL Co.,Ltd's Equity Buyback Plan announced on June 14, 2022. CI
GemVax&KAEL Co.,Ltd announces an Equity Buyback for 150,000 shares. CI
GemVax&KAEL Co.,Ltd authorizes a Buyback Plan. CI
Tranche Update on GemVax&KAEL Co.,Ltd's Equity Buyback Plan announced on April 13, 2022. CI
GemVax&KAEL Co.,Ltd's Equity Buyback announced on April 13, 2022, has closed with 300,000 shares, representing 0.76% for KRW 4,333.75 million. CI
GemVax&KAEL Co.,Ltd announces an Equity Buyback for 300,000 shares. CI
GemVax&KAEL Co.,Ltd authorizes a Buyback Plan. CI
GemVax&KAEL Co.,Ltd(KOSDAQ:A082270) added to S&P Global BMI Index CI
GemVax&KAEL Co.,Ltd acquired additional 12.9% stake in Gemvaxlink Co., Ltd. for KRW 18 billion. CI
GemVax&KAEL Co.,Ltd acquired additional 12.99% stake in Gemvaxzio Co., Ltd. for KRW 18.02 billion. CI
GemVax's Highly Promising Phase II Alzheimer's Disease Clinical Trial Results Targeting Telomerase Published in Alzheimer's Research & Therapy' Journal CI
GemVax&KAEL Co.,Ltd(KOSDAQ:A082270) dropped from S&P Global BMI Index CI
More news
1 day-0.18%
1 week+0.18%
Current month-6.11%
1 month-8.14%
3 months-16.90%
6 months-18.50%
Current year-16.72%
More quotes
1 week
10 950.00
Extreme 10950
11 330.00
1 month
10 950.00
Extreme 10950
12 090.00
Current year
10 950.00
Extreme 10950
15 310.00
1 year
10 950.00
Extreme 10950
17 440.00
3 years
10 950.00
Extreme 10950
26 250.00
5 years
9 960.00
Extreme 9960
43 550.00
10 years
9 960.00
Extreme 9960
45 650.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 -
Comptroller/Controller/Auditor 68 19-03-28
Members of the board TitleAgeSince
Chief Executive Officer 57 -
Director/Board Member 56 23-03-29
Director/Board Member 67 22-03-30
More insiders
Date Price Change Volume
24-04-24 11,060 -0.18% 56 744
24-04-24 11,080 +0.36% 53,240
24-04-23 11,040 -0.36% 37,981
24-04-22 11,080 +0.73% 70,372
24-04-19 11,000 -1.08% 82,063

End-of-day quote Korea S.E., April 24, 2024

More quotes
GemVax & KAEL Co.,Ltd is a Korea-based company mainly engaged in the manufacture of pollution control equipment used in semiconductor manufacturing processes. The Company and its subsidiaries are engaged in the three categories of businesses: pollution control business, which manufactures chemical air (CA) filters, gas scrubbers, resins, coating resins and other environmental equipments and systems; anticancer and anti-inflammation business, which engages in development of cancer vaccines for infectious diseases, such as acquired immune deficiency syndrome (AIDS) and anti-inflammations, and IT business which mainly produces liquid crystal display (LCD) modules. The Company distributes its products within domestic market and to overseas markets.
More about the company
  1. Stock Market
  2. Equities
  3. A082270 Stock